Advanced/Recurrent Non-small-cell Lung Cancer Completed Phase 1 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0049610 (Advanced/Recurrent Non-small-cell Lung Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01251796A Study of ARQ 197 in Combination With ErlotinibTreatment